Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Share-based Compensation (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Share-based Compensation for 7 consecutive years, with $29000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Share-based Compensation fell 98.73% year-over-year to $29000.0, compared with a TTM value of -$1.7 million through Dec 2019, down 117.79%, and an annual FY2024 reading of $8.8 million, up 15.51% over the prior year.
  • Share-based Compensation was $29000.0 for Q4 2019 at Larimar Therapeutics, up from -$3.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.9 million in Q2 2016 and bottomed at -$3.9 million in Q3 2019.
  • Average Share-based Compensation over 5 years is $1.7 million, with a median of $2.1 million recorded in 2017.
  • The sharpest move saw Share-based Compensation soared 623.51% in 2015, then crashed 275.05% in 2019.
  • Year by year, Share-based Compensation stood at $2.7 million in 2015, then plummeted by 33.44% to $1.8 million in 2016, then rose by 15.05% to $2.1 million in 2017, then increased by 8.94% to $2.3 million in 2018, then plummeted by 98.73% to $29000.0 in 2019.
  • Business Quant data shows Share-based Compensation for LRMR at $29000.0 in Q4 2019, -$3.9 million in Q3 2019, and $33000.0 in Q2 2019.